secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-02-09T23:59:59+00:00
Accession:  0001213900-24-011954
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed appoints Netta Jagpal as CFO and Corporate Secretary effective Feb 20, 2024
--------------------------------------------------------------------------------

- Netta Jagpal appointed CFO and Corporate Secretary effective Feb 20, 2024; replaces Jonathan Tegge as Interim CFO.
- Annual base salary of CAD$325,000; eligible for annual discretionary bonus target of 40% of base salary.
- Initial grant of 50,000 stock options subject to corporate approvals under the company's stock option plan.
- Ms. Jagpal brings over 20 years of biotech finance experience from D-Wave Systems, Zymeworks, Angiotech, and Ernst & Young.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024011954/0001213900-24-011954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024011954/ea193307-8k_inmedpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-011954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer